As per the official website of Aurobindo Pharma Sharath Chandra Reddy, a graduate of Business Administration and is a second-generation entrepreneur belonging to the promoter group.
They were arrested under the Prevention of Money Laundering Act following day-long questioning with them here at the Enforcement Directorate headquarters on Wednesday.
The businessmen will be produced before a special court later in the day in the national capital.
Reddy is the head of a Hyderabad-based Aurobindo Pharma company and is engaged in the liquor business. However, Babu is the head of a company named Pernord Ricard.
Both the businessmen were held based on their involvement in ED's ongoing investigation in the Delhi Excise Policy money laundering case, said the sources.
The move comes days after the Enforcement Directorate on questioned Delhi Deputy Chief Minister Manish Sisodia's personal assistant, Devendra Sharma, followed by raids conducted at five places in Delhi and the National Capital Region (NCR) in the case.
The agency is also learnt to have picked a few suspects, including Devendra Sharma, a close aide and personal assistant of Sisodia, from their houses in Delhi and NCR.
In October, the ED had raided nearly three dozen locations in Delhi and Punjab following the arrest of Sameer Mahendru, Managing Director of Delhi's Jor Bagh-based liquor distributor Indospirit Group, in the case.
Among the accused in the case are Delhi Deputy Chief Minister Manish Sisodia, the then Excise Commissioner Arva Gopi Krishna, Deputy Commissioner Anand Tiwari and Assistant Commissioner Pankaj Bhatnagar.
Other accused are Manoj Rai, a former employee of Pernod Ricard; Amandeep Dhal, director of Brindco Sales; director of Buddy Retail Amit Arora, and Dinesh Arora; authorised signatories of Mahadev Liquors Sunny Marwah, Arun Ramchandra Pillai and Arjun Pandey.
On September 27, the Central Bureau of Investigation (CBI) arrested businessman Vijay Nair, former CEO of event management company Only Much Louder, during the investigation in relation to the Delhi excise policy scam.
Abhishek Boinpally was arrested by CBI recently in an ongoing investigation of a case related to the alleged irregularities in framing and implementation of the excise policy of the Delhi government.
Abhishek Boinpally was part of the conspiracy in pursuance of which, he transferred money through hawala channels to co-accused Vijay Nair through co-accused Dinesh Arora prior to the implementation of the policy during the period November 2021 to July 2022, CBI said.
The ED and the CBI had alleged that irregularities were committed while modifying the Excise Policy, undue favours were extended to licence holders, the licence fee was waived or reduced and the L-1 licence was extended without the competent authority's approval. The beneficiaries diverted "illegal" gains to the accused officials and made false entries in their books of account to evade detection.
An alleged, the Excise Department had decided to refund the Earnest Money Deposit of about Rs 30 crore to a successful tenderer against the set rules. Even though there was no enabling provision, a waiver on tendered licence fees was allowed from December 28, 2021, to January 27, 2022, due to COVID-19.
This allegedly caused a loss of Rs 144.36 crore to the exchequer, said the FIR, which has been instituted on a reference from the Union Home Ministry following a recommendation from Delhi Lieutenant-Governor Vinai Kumar Saxena.
In August, CBI registered a case in an excise policy scam and issued a Look Out Circular (LOC) against eight private persons named as accused in the case.
A total of nine private persons have been named in the FIR. Except for Manoj Rai, ex-vice president of Pernod Ricard, LOC has been issued against all private persons.
Aurobindo Pharma Limited is a global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 155 countries.
The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic, supported by a strong R&D set-up.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.